<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>79(5)</volume><submitter>Deroyer C</submitter><funding>Fond d’Investissement pour la Recherche Scientifique</funding><funding>Crédit Sectoriel de Recherche en Sciences de la Santé</funding><pubmed_abstract>Osteoarthritis (OA) synovial membrane is mainly characterized by low-grade inflammation, hyperplasia with increased cell proliferation and fibrosis. We previously underscored a critical role for CEMIP in fibrosis of OA cartilage. However, its role in OA synovial membrane remains unknown. An in vitro model with fibroblast-like synoviocytes from OA patients and an in vivo model with collagenase-induced OA mice were used to evaluate CEMIP-silencing effects on inflammation, hyperplasia and fibrosis. Our results showed that i. CEMIP expression was increased in human and mouse inflamed synovial membrane; ii. CEMIP regulated the inflammatory response pathway and inflammatory cytokines production in vitro and in vivo; iii. CEMIP induced epithelial to mesenchymal transition pathway and fibrotic mar</pubmed_abstract><journal>Cellular and molecular life sciences : CMLS</journal><pagination>260</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9042994</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>CEMIP (KIAA1199) regulates inflammation, hyperplasia and fibrosis in osteoarthritis synovial membrane.</pubmed_title><pmcid>PMC9042994</pmcid><pubmed_authors>Paulissen G</pubmed_authors><pubmed_authors>Poulet C</pubmed_authors><pubmed_authors>Deroyer C</pubmed_authors><pubmed_authors>Malaise MG</pubmed_authors><pubmed_authors>Cobraiville G</pubmed_authors><pubmed_authors>Malaise O</pubmed_authors><pubmed_authors>Plener Z</pubmed_authors><pubmed_authors>Daniel C</pubmed_authors><pubmed_authors>Ciregia F</pubmed_authors><pubmed_authors>de Seny D</pubmed_authors><pubmed_authors>Gillet P</pubmed_authors></additional><is_claimable>false</is_claimable><name>CEMIP (KIAA1199) regulates inflammation, hyperplasia and fibrosis in osteoarthritis synovial membrane.</name><description>Osteoarthritis (OA) synovial membrane is mainly characterized by low-grade inflammation, hyperplasia with increased cell proliferation and fibrosis. We previously underscored a critical role for CEMIP in fibrosis of OA cartilage. However, its role in OA synovial membrane remains unknown. An in vitro model with fibroblast-like synoviocytes from OA patients and an in vivo model with collagenase-induced OA mice were used to evaluate CEMIP-silencing effects on inflammation, hyperplasia and fibrosis. Our results showed that i. CEMIP expression was increased in human and mouse inflamed synovial membrane; ii. CEMIP regulated the inflammatory response pathway and inflammatory cytokines production in vitro and in vivo; iii. CEMIP induced epithelial to mesenchymal transition pathway and fibrotic mar</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Apr</publication><modification>2025-05-18T12:07:03.376Z</modification><creation>2025-02-19T03:58:21.685Z</creation></dates><accession>S-EPMC9042994</accession><cross_references><pubmed>35474501</pubmed><doi>10.1007/s00018-022-04282-6</doi></cross_references></HashMap>